These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
541 related articles for article (PubMed ID: 22560334)
1. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells. Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334 [TBL] [Abstract][Full Text] [Related]
2. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R Exp Cell Res; 2009 Feb; 315(3):485-97. PubMed ID: 19071109 [TBL] [Abstract][Full Text] [Related]
3. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma. Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240 [TBL] [Abstract][Full Text] [Related]
4. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. Schult C; Dahlhaus M; Glass A; Fischer K; Lange S; Freund M; Junghanss C Anticancer Res; 2012 Feb; 32(2):463-74. PubMed ID: 22287733 [TBL] [Abstract][Full Text] [Related]
5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292 [TBL] [Abstract][Full Text] [Related]
6. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells. Brünner-Kubath C; Shabbir W; Saferding V; Wagner R; Singer CF; Valent P; Berger W; Marian B; Zielinski CC; Grusch M; Grunt TW Breast Cancer Res Treat; 2011 Sep; 129(2):387-400. PubMed ID: 21046231 [TBL] [Abstract][Full Text] [Related]
7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560 [TBL] [Abstract][Full Text] [Related]
8. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma. Doghman M; Lalli E Mol Cell Endocrinol; 2012 Nov; 364(1-2):101-4. PubMed ID: 22960230 [TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. Civallero M; Cosenza M; Marcheselli L; Pozzi S; Sacchi S Expert Opin Investig Drugs; 2012 Nov; 21(11):1597-606. PubMed ID: 22920938 [TBL] [Abstract][Full Text] [Related]
11. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Masuda M; Shimomura M; Kobayashi K; Kojima S; Nakatsura T Oncol Rep; 2011 Nov; 26(5):1273-9. PubMed ID: 21725613 [TBL] [Abstract][Full Text] [Related]
12. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518 [TBL] [Abstract][Full Text] [Related]
13. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803 [TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
17. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547 [TBL] [Abstract][Full Text] [Related]
18. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma. Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389 [TBL] [Abstract][Full Text] [Related]
19. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462 [TBL] [Abstract][Full Text] [Related]
20. The phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 is effective in inhibiting regrowth of tumour cells after cytotoxic therapy. Hernlund E; Olofsson MH; Fayad W; Fryknäs M; Lesiak-Mieczkowska K; Zhang X; Brnjic S; Schmidt V; D'Arcy P; Sjöblom T; De Milito A; Larsson R; Linder S Eur J Cancer; 2012 Feb; 48(3):396-406. PubMed ID: 22154651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]